STOUFFER’S®, provider of premium-quality frozen entrees, today announced that it will be simplifying recipes according to its new “Kitchen Cupboard” commitment. This new initiative will focus on shortening and simplifying recipes and only including ingredients consumers might find at home, like vine-ripened tomatoes, freshly made pasta, and real mozzarella.
This effort will begin with STOUFFER’S Lasagna with Meat and Sauce, one of the brand’s classic offerings. The simpler recipe will now contain fewer ingredients, but continue to offer the same great taste consumers know and love.
“What you put on the table matters to you, which is why what we put into each dish matters to us,” said Chef Robert Fedorko, Director of Culinary Innovation of Nestlé USA, STOUFFER’S parent company. “STOUFFER’S upholds a standard of providing great tasting meals made with quality ingredients and culinary expertise. We’re excited to share our Kitchen Cupboard commitment so that consumers can continue to feel confident in serving STOUFFER’S meals to their families.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7904951-stouffers-kitchen-cupboard-commitment/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
When a child is diagnosed with cancer, their family is presented with treatment options – often a combination of surgery, radiation and chemotherapy. Radiation and chemotherapy have been used to treat kids’ cancers for more than 50 years and often come with long-term late effects including secondary cancers, heart damage and cognitive issues. Often a child’s best chance at survival is a clinical trial which offers them the newest treatment options available.
In recognition of Childhood Cancer Awareness Month, the St. Baldrick’s Foundation will highlight the critical need to fund lifesaving research and share stories of kids affected by cancer – like Micah, who is alive today because there was a clinical trial available.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284352-st-baldricks-foundation-conquer-childhood-cancers/
What does it look like to really live a full life – one that enriches and satisfies, that provides happiness and enables achievement? Abbott is talking to one million people worldwide to find out. And the answers aren’t as simple as you would think.
Does living fully look the same to an accountant in Shanghai as it does to an architect in New Delhi or a street artist in São Paulo? What about a factory worker in Detroit or a new mother in Berlin? In today’s hyperconnected world that is pulling us together in so many ways, how do our cultural differences, life experiences and personalities influence what it means to live a full life?
Early in this quest we’re seeing preliminary trends, like the role health plays in a full life in Shanghai and the importance of family in New York. We’ll have to see if this is confirmed as we go global with our research. The one thing that is becoming apparent is just how personal it gets when we talk to people about life.
This global quest is at the heart of what our company does—finding answers that have helped people live healthier, better lives for more than 125 years.
To view the multimedia release go to:
http://www.multivu.com/players/English/7611051-abbott-live-fully/
GB Sciences, Inc. (OTCQB: GBLX) announces the success of its first annual, “Innovation in Medical Cannabis Therapies” (IMCT) Symposium, held on Friday, November 9th at the “Keep Memory Alive” Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day’s program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price.
To view the multimedia release go to:
https://www.multivu.com/players/English/8308958-gb-sciences-2018-medical-cannabis-therapies-symposium/
Mary Murphy partners with Osteo Bi-Flex®
The GUINNESS WORLD RECORDS™ Title for the ‘Largest merengue lesson’ has officially been set as of Friday, April 15, by none other than joint supplement Osteo Bi-Flex. Led by celebrity choreographer Mary Murphy, ballroom dancing champion, at the Fremont Street Experience, the lesson involved more than 250 participants who gathered to learn and perform the high-energy, Latin-inspired merengue.
Record attempt participants stepped in time throughout the half-hour lesson, under the expert direction of celebrity dancer and choreographer Mary Murphy.
The joint support supplement’s record-breaking feat was held as a celebration of movement, encouraging folks to be active and to continue enjoying the activities that make them happy at any age.
“Osteo Bi-Flex is leading the call for movement and enabling individuals to continue participating in the activities they love by facilitating joint comfort, flexibility and movement,” said Derek Bowen, Senior Vice President for Osteo Bi-Flex. “Our product has been helping people for years, so to have our name down in the record books for getting people moving is a perfect fit with our brand! From our standpoint, stillness is the new smoking. Taking Osteo Bi-Flex will help people feel more comfortable within 7 days of taking it.*”
To view the multimedia release go to:
http://www.multivu.com/players/English/7796951-osteo-bi-flex-guinness-world-record/
Today, WebMD Health Corp. (NASDAQ: WBMD) announced new features and functionality for its Healthy Target behavior change program that connects seamlessly with Apple’s HealthKit and provides users with powerful new ways to capture, visualize and understand health information from a broad range of biometric devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70402511-web-md-updates-healthy-target-behavior-change-program-apple-healthkit/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For Africa and Arab States
Prof. Khalid Mohammed AlGhamdi from Saudi Arabia
Charity Society known as Faal to empower and support vitiligo patients in Saudi Arabia
Vitiligo is a long-term skin condition that causes pale, white patches on the skin due to a lack of melanin. This project aimed to increase awareness via TV broadcasts, schools visits and to provide psychological and social support to patients with vitiligo through training courses and different education programs.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
One of the first steps to take when you have decided that you want to do something about your health is to do a colon and blood cleanse.
Hi Rudy, Again,
Not only should you do this cleanse to improve your health, but when you fall ill to any disease as simple as constant mucus flow, skin eruptions, or to a deadly disease such as cancer.
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
Dr. Ksenia Sorokina from Russia
A healthy child means a healthy family- Targeting prevention of dermatitis and adherence to treatment
This project consists of providing training workshops for parents and children with chronic skin diseases and developing the first ever website to allow patients living in remote areas of the Russian Federation to access a consultation with a dermatologist, as well as attend online training seminars for people presenting chronic dermatitis and to increase adherence to therapy for patients as well as their parents, within four Russian territories.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
